Nanjing Medlander Medical Technology Co. Ltd. Class A

Nanjing Medlander Medical Technology Co. Ltd. Class A

SSSE:688273
27.44
CNY
+1.12
(+4.26%)
0.65EPS
57.14P/E
3.87BMarket Cap
Oct 29Next Earn
Nanjing Medlander Medical Technology Co. Ltd. Class A
SSE:688273
(Shanghai Stock Exchange)

Recent

price

27.44

P/E

ratio

57.14

div

yld

4.20%

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.91
2.56
4.49
4.56
4.52
3.41
4.31
4.41
4.06
Revenue per Share
0.75
1.06
1.63
1.58
1.46
0.9
1.03
1.05
0.68
Basic EPS, GAAP
0.24
0.59
1.4
1.79
0.87
0.62
-0.07
-0.13
- -
Free Cash Flow per Basic Share
0.21
0.65
0.72
- -
0.6
0.82
1
0.7
1.15
Dividend per Share
1.61
2.05
3.21
4.85
13.5
13.37
13.12
13.45
13.35
Book Value per Share
1.61
2.05
3.09
4.74
13.31
13.06
12.1
12.45
12.38
Tangible Book Value per Share
75
100
75
75
83
100
99
98
99
Basic Weighted Avg Shares
143
256
337
342
377
341
425
432
404
Sales/Revenue/Turnover
41.64
44.1
40.22
36.6
35.08
21.84
26.51
23.58
15.73
Operating Margin (%)
1
3
6
11
14
18
27
30
- -
Depreciation Expense
56
106
122
118
122
90
102
103
67
Net Income, GAAP
9.06
8.85
12.01
7.74
11.38
8.87
12.97
6.13
1.02
Effective Tax Rate (%)
39.03
41.49
36.23
34.65
32.29
26.35
23.93
23.78
16.7
Profit Margin (%)
54
40
113
241
1,197
1,039
839
710
643
Working Capital
- -
- -
- -
4
8
2
1
9
7
LT Debt
121
158
247
373
1,370
1,375
1,347
1,370
1,356
Total Equity
- -
61.57
53.06
36.57
14.49
6.72
7.23
7.23
4.65
Return on Invested Capital (%)
- -
67.8
57.04
36.86
13.01
6.33
6.93
7.72
5.14
Return on Capital (%)
- -
77.25
61.82
39.2
14.2
6.66
7.64
7.72
5.02
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
24
28
29
LT Borrowings
- -
- -
- -
LT Finance Leases
9
8
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
100
Market Capitalization
4,252
3,755
3,874

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
931
922
865
Cash, Cash Equivalents & STI
816
788
723
Accounts Receivable, Net
28
38
38
Inventories
72
73
81
Total Current Liabilities
221
189
222
Payables & Accruals
- -
- -
- -
ST Debt
24
28
29
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
63.63%
1.68%
Free Cash Flow
- -
-13.63%
76.79%
Net Income, GAAP
- -
-2.44%
1.03%
Sales/Revenue/Turnover
- -
5.7%
1.66%
Total Cash Common Dividend
- -
30,628.48%
-30.54%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
104
124
102
94
425
2025
118
123
- -
88
432
2026
99
94
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.37
0.36
0.24
0.06
1.03
2025
0.41
0.24
- -
0.07
1.05
2026
0.23
0.14
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.56
0.2
0.23
1
2025
- -
0.37
- -
0.29
0.7
2026
- -
0.49
- -
- -
- -
Business
Nanjing Medlander Medical Technology Co., Ltd. develops, manufactures, and commercializes medical devices, clinical consumables, and healthcare software solutions focused on pelvic floor health, obstetrics and gynecology rehabilitation, reproductive medicine, medical aesthetics, and neuromodulation. The company operates through several specialized product and service segments, including Pelvic Floor and Postpartum Rehabilitation Equipment, comprising biological feedback and electrical stimulation devices under the MLD B and MLD M series, high-intensity pulsed magnetic stimulation systems, pelvic surface electromyography analysis systems, and the PI-ONE intelligent pelvic diagnosis and treatment platform; Reproductive Rehabilitation and Anti-Aging Systems, featuring electro-ultrasound therapy systems and multimodal acoustic, optical, electrical, thermal, and magnetic therapeutic devices marketed under brand lines such as Weizhilan; Medical Consumables and Accessories, providing specialized vaginal electrodes, rectal electrodes, and clinical probes designed for pelvic assessment and treatment; Movement and Motor Rehabilitation Systems, including hand-function magnetic stimulation devices and joint rehabilitation assessment tools; Medical Aesthetic and Dermatological Devices, consisting of AI-powered skin analysis systems, therapeutic ultrasound systems for facial wrinkle reduction, and Nd:YAG picosecond laser treatment platforms; and Clinical Informatics Solutions, delivering cloud-based pelvic healthcare management software and hospital-grade tiered diagnosis and treatment platforms. The company serves public and private general hospitals, maternal and child healthcare institutions, obstetrics and gynecology departments, pelvic rehabilitation centers, urology and anorectal clinics, reproductive medicine centers, postpartum recovery institutions, and medical aesthetic clinics primarily throughout China as well as international markets across Asia and the Middle East. Founded in 2013 and headquartered in Nanjing, China, the company trades on the Shanghai Stock Exchange STAR Market under ticker 688273. In recent corporate developments, Nanjing Medlander Medical Technology Co., Ltd. has executed a strategic transition toward a dual-engine growth model integrating clinical medical equipment with consumer healthcare and neuro-rehabilitation technologies. Recent operational highlights include entering into a strategic partnership with Beauty Farm to advance gynecological anti-aging research and clinical applications; establishing strategic research and clinical collaboration with Hangzhou Rongnao Technology Co., Ltd. alongside a strategic equity investment to co-develop brain-computer interface and neural modulation technologies; securing Class II medical device regulatory approvals for its proprietary ultrasound therapy system for facial skin firming and its Nd:YAG picosecond laser therapy system; and integrating generative AI algorithms into its dermatological diagnostic tools and digital pelvic diagnosis workflows.